1
Cruijsen, M, van der Velden, W J F M, de Haan, A F J, Klein, S K, Hoogendoorn, M, Tromp, Y, de Valk, B, van Rees, B, de Boer, F, van der Spek, E, Pruijt, J, Verdonck, L F, Vellenga, E, Blijlevens, N, van de Loosdrecht, A A, Huls, G
Veröffentlicht in: Cruijsen , M , van der Velden , W J F M , de Haan , A F J , Klein , S K , Hoogendoorn , M , Tromp , Y , de Valk , B , van Rees , B , de Boer , F , van der Spek , E , Pruijt , J , Verdonck , L F , Vellenga , E , Blijlevens , N , van de Loosdrecht , A A & Huls , G 2020 , ' Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study ' , Leukemia & Lymphoma , vol. 61 , no. 11 , pp. 2752-2755 . https://doi.org/10.1080/10428194.2020.1775217;
2020
Veröffentlicht in: Cruijsen , M , van der Velden , W J F M , de Haan , A F J , Klein , S K , Hoogendoorn , M , Tromp , Y , de Valk , B , van Rees , B , de Boer , F , van der Spek , E , Pruijt , J , Verdonck , L F , Vellenga , E , Blijlevens , N , van de Loosdrecht , A A & Huls , G 2020 , ' Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study ' , Leukemia & Lymphoma , vol. 61 , no. 11 , pp. 2752-2755 . https://doi.org/10.1080/10428194.2020.1775217;
2020
2
3
4
5
6
7